Sign in
Axicabtagene Ciloleucel in Patients with Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1
Journal article   Peer reviewed

Axicabtagene Ciloleucel in Patients with Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1

Frederick L. Locke, Armin Ghobadi, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Eric Jacobsen, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, …
Clinical lymphoma, myeloma and leukemia, Vol.18, p.S276
2018-09

Metrics

5 Record Views

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

undefined

Source: InCites

Details